Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses

Molecular Pharmacology

Volumn 71, Issue 5, 2007, Pages 1389-1398

  Chen, Yelin ^a   Nong, Yi ^a   Goudet, Cyril ^b,c,d,e   Hemstapat, Kamondanai ^a   De Paulis, Tomas ^a   Pin, Jean Philippe ^b,c,d,e   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^c CNRS   (France)

^d INSERM   (France)

^e UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 3,3' DIFLUOROBENZALDAZINE; 4 NITRO N (11,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; BENZAMIDE DERIVATIVE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N [4 CHLORO 2 [(1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)METHYL]PHENYL] 2 HYDROXYBENZAMIDE; UNCLASSIFIED DRUG; VU 29;

ALLOSTERISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MALE; MESENCEPHALON; MUTATION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BENZAMIDES; BINDING, COMPETITIVE; CELL LINE; DRUG SYNERGISM; GLYCINE; HUMANS; MALE; MUTATION; NEURONS; PYRAZOLES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RESORCINOLS; SUBSTANTIA NIGRA; SUBSTRATE SPECIFICITY; SUBTHALAMIC NUCLEUS;

EID: 34247477329     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.032425     Document Type: Article

References (40)

1. Alagille D, Baldwin RM, Roth BL, Wroblewski JT, Grajkowska E, and Tamagnan GD (2005a) Functionalization at position 3 of the phenyl ring of the potent mGluR5 noncompetitive antagonists MPEP. Bioorg Med Chem Lett 15:945-949.
2. Alagille D, Baldwin RM, Roth BL, Wroblewski JT, Grajkowska E, and Tamagnan GD (2005b) Synthesis and receptor assay of aromatic-ethynyl-aromatic derivatives with potent mGluR5 antagonist activity. Bioorg Med Chem 13:197-209.
3. Awad H, Hubert GW, Smith Y, Levey AI, and Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
4. Bhave G, Nadin BM, Brasier DJ, Glauner KS, Shah RD, Heinemann SF, Karim F, and Gereau RW 4th (2003) Membrane topology of a metabotropic glutamate receptor. J Biol Chem 278:30294-30301.
5. Chen Y, Rodriguez AL, and Conn PJ (2004) Two structurally distinct allosteric potentiators of mGluR5 act on different sites of the receptor. Soc Neurosci Abstr 30:627.14.
6. Chojnacka-Wojcik E, Klodzinska A, and Pilc A (2001) Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs 2:1112-1119.
7. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237.
8. Cosford ND, Roppe J, Tehrani L, Schweiger EJ, Seiders TJ, Chaudary A, Rao S, and Varney MA (2003) [3H]-Methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 13:351-354.
9. Coutinho V and Knopfel T (2002) Metabotropic glutamate receptors: electrical and chemical signaling properties. Neuroscientist 8:551-561.
10. de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, and Conn PJ (2006) Substituent effects of N-(1,3-diphenyl- 1Hpyrazol-5yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J Med Chem 49:3332-3344.
11. Doherty J and Dingledine R (2002) The roles of metabotropic glutamate receptors in seizures and epilepsy. Curr Drug Target CNS Neurol Disord 1:251-260.
12. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T, and Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 318:173-185.
13. Gasparini F, Kuhn R, and Pin JP (2002) Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2:43-49.
14. Gasparini F, Lingenhohl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38:1493-1503.
15. Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, Acher F, Prezeau L, and Pin JP (2004) Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci USA 101:378-383.
16. Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, Tamagnan GD, and Conn PJ (2006) A novel class of positive allosteric modulators of mGluR1 interact with a site distinct from that of negative allosteric modulators. Mol Pharmacol 70:616-626.
17. Iso Y, Grajkowska E, Wroblewski JT, Davis J, Goeders NE, Johnson KM, Sanker S, Roth BL, Tueckmantel W, and Kozikowski AP (2006) Synthesis and structureactivity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonist: search for cocaine medications. J Med Chem 49:1080-1100.
18. Jingami H, Nakanishi S, and Morikawa K (2003) Structure of the metabotropic glutamate receptor. Curr Opin Neurobiol 13:271-278.
19. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, et al. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206.
20. Knoflach F, Mutel V, Jolidon S, Kew JN, Malherbe P, Vieira E, Wichmann J, and Kemp JA (2001) Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc Natl Acad Sci USA 98:13402-13407.
21. Lindsley CW, Wisnoski DD, Leister WH, O'Brien JA, Lemaire W, Williams DL Jr, Burno M, Sur C, Kinney GG, Pettibone DJ, et al. (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides. J Med Chem 47:5825-5828.
22. Malherbe P, Kratochwil N, Zenner MT, Piussi J, Diener C, Kratzeisen C, Fischer C, and Porter RH (2003) Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Mol Pharmacol 64:823-832.
23. Marino MJ, Awad-Granko H, Ciombor KJ, and Conn PJ (2002) Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulate. Neuropharmacology 43:147-159.
24. Marino MJ and Conn PJ (2002a) Direct and indirect modulation of the N-methyl-D-aspartate receptor. Curr Drug Target CNS Neurol Disord 1:1-16.
25. Marino MJ and Conn PJ (2002b) Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. Curr Drug Target CNS Neurol Disord 1:239-250.
26. Marino MJ, Williams DL Jr, O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG, et al. (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci USA 100:13668-13673.
27. Marino MJ, Wittmann M, Bradley SR, Hubert GW, Smith Y, and Conn PJ (2001) Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. J Neurosci 21:7001-7012.
28. May LT and Christopoulos A (2003) Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 3:551-556.
29. O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, et al. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5) Mol Pharmacol 64:731-740.
30. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, et al. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther 309:568-577.
31. O'Hara PJ, Sheppard PO, Thogersen H, Venezia D, Haldeman BA, McGrane V, Houamed KM, Thomsen C, Gilbert TL, and Mulvihill ER (1993) The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. Neuron 11:41-52.
32. Pagano A, Ruegg D, Litschig S, Stoehr N, Stierlin C, Heinrich M, Floersheim P, Prezeau L, Carroll F, Pin JP, et al. (2000) The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b] chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J Biol Chem 275:33750-33758.
33. Palucha A and Pilc A (2002) On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants. Pol J Pharmacol 54:581-586.
34. Peavy RD, Chang MS, Sanders-Bush E, and Conn PJ (2001) Metabotropic glutamate receptor 5-induced phosphorylation of extracellular signal-regulated kinase in astrocytes depends on transactivation of the epidermal growth factor receptor. J Neurosci 21:9619-9628.
35. Pilc A (2003) LY-354740 (Eli Lilly). IDrugs 6:66-71.
36. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, Conn PJ (2005) A close structural analog of MPEP acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68:1793-1802.
37. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, Rao SP, Bain G, Pinkerton AB, Vernier JM, et al. (2003) Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 64:798-810.
38. Varney MA and Gereau RW 4th (2002) Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Target CNS Neurol Disord 1:283-296.
39. Wisniewski K and Carr H (2002) (S)-3,5-DHPG: a review. CNS Drug Rev 8:101-116.
40. Zhang Y, Rodriguez AL, and Conn PJ (2005) Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 315:1212-1219.